Vasant Narasimhan

Last updated
Vasant Kalathur Narasimhan
M.D.
Vasant Narasimhan.jpg
Vasant Narasimhan
Born (1976-08-26) August 26, 1976 (age 47)
Pittsburgh, Pennsylvania, U.S.
Nationality American
Education University of Chicago
Harvard Medical School
Harvard University, Kennedy School of Government
Occupation CEO of Novartis
Spouse
Srishti Gupta
​
(m. 2003)​
Children2
Medical career
Profession Physician
Institutions Novartis

Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. [1] [2] [3] [4] He succeeded Joseph Jimenez who left Novartis in 2018. [5] He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical Officer. [6]

Contents

Early life

Narasimhan was born in Pittsburgh in 1976 to parents who originated from Tamil Nadu, India. [7] His parents came to the US from India in the 1960’s and early 1970’s and started the Shri Venkateshwara temple in Penn Hills, Pittsburgh which he has stated was influential in his upbringing. Narasimhan's mother was a nuclear engineer for Public Service Electric and Gas Company and his father was an executive at Hoeganaes Corporation. [8] [9]

Narasimhan received his bachelor's degree in biological sciences from University of Chicago, his M.D. from Harvard Medical School and his master's degree in public policy from the John F. Kennedy School of Government. [10]

During his undergraduate and post-graduate studies, he worked on public health programs including the National HIV Treatment Program in Botswana, the American Red Cross in The Gambia and child poverty in India. Paul Farmer and Jim Kim were his mentors and thesis advisors. [11] [12] [13] [14] [15] [8] [9]

Career

Early career

After his first year of medical school, Vas went to Kolkata, India to work with street children and child laborers for 3 months. He later worked on malaria and HIV/AIDS in Tanzania and he did his thesis on multidrug resistant tuberculosis in Peru. [9] [16] [6]

Narasimhan joined McKinsey & Co, as a consultant and engagement manager for two years and was recruited by Novartis in 2005. [16] [6]

He spent 8 years working in Novartis Vaccines, at the time a non-profit division focused on developing vaccines for children and patients around the world and served as the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17]

From 2014 to 2016, he served as the Global Head of Development for Novartis Pharmaceuticals. From 2016 to 2018, he held the role of Global Head of Drug Development and Chief Medical Officer within the company. [6]

Novartis Chief Executive (2017 – present)

On September 5, 2017, Narasimhan was named CEO of Novartis, succeeding Joseph Jimenez. [5] [18] [19]

He publicly stated his desire to focus Novartis from a diversified company to a pure-play medicines company. [20] He also advocated for development of key technologies and capabilities in advanced therapy platforms, such as cell therapy and gene therapy, [21] RNA therapeutics, and radioligand therapy. [22] [23]

As part of his strategy, Narasimhan has divested the joint consumer healthcare venture to GSK, [24] the spin-off of Alcon, [25] and the exit of a stake in Roche [26] [20] as well as pushed for the acquisition of Advanced Accelerator Applications, Endocyte, AveXis, and The Medicines Company. [27] [28] [29]

In February 2018, three months after becoming CEO, Narasimhan apologized to Novartis employees after it was revealed that Novartis had signed a $1.2 million yearlong contract with President Donald Trump's personal attorney Michael Cohen's consulting firm in February 2017. [30] [31]

In 2019, in response to an FDA investigation about manipulated data involving Zolgensma, Narasimhan defended the company's decision to delay informing the FDA and also announced the company was forcing out scientists who were involved in the manipulated data. [32] [33] [34]

As part of a "more comprehensive commitment to ethics”, Narasimhan has moved to settle long standing bribery and anti-trust cases facing Novartis in the US, China, Vietnam and Greece. [35] [36] [37]

Memberships

Narasimhan is a member of the U.S. National Academy of Medicine and a member of the board of fellows of Harvard Medical School. [38] [39] Since February 2023, he serves as the chair, and is also former board member and treasurer of the Pharmaceutical Research and Manufacturers of America (PhRMA). [40] [41]

He also serves on the board of African Parks, a nonprofit conservation organization, and since December 2022 is the chair of the board. [42] [43]

Recognition

In 2015, Fortune listed Narasimhan 7th in their '40 under 40' list. [44]

Personal life

Narasimhan married Srishti Gupta in 2003, after meeting her at Harvard while organizing an Asian cultural festival. [45] They have two children and live in Basel, Switzerland. [17] Narasimhan is a vegetarian. [46] [47]

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Pharmaceutical Research and Manufacturers of America</span> Trade group

Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland. Sandoz is one of the leading global generics businesses.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma–based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

<span class="mw-page-title-main">Joseph Jimenez</span>

Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.

<span class="mw-page-title-main">Incyte</span> American pharmaceutical company

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

<span class="mw-page-title-main">Ceritinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Ceritinib is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014.

Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer.

Onasemnogene abeparvovec, sold under the brand name Zolgensma, is a gene therapy used to treat spinal muscular atrophy (SMA), a disease causing muscle function loss in children. It involves a one-time infusion of the medication into a vein. It works by providing a new copy of the SMN gene that produces the SMN protein.

Novartis Gene Therapies, until 2020 known as AveXis, is a biotechnology company that develops treatments for rare neurological genetic disorders. It was founded in Dallas, Texas, United States in 2012 by John Carbona after reorganizing a company called BioLife Cell Bank founded by David Genecov and John Harkey. Work done at Nationwide Children's Hospital in the laboratory of Brian Kaspar was licensed to AveXis in October 2013. Unusual for the time, Nationwide Children's Hospital, in addition to upfront and milestone payments, also took an equity position in AveXis. Kaspar became paid consultant pari passu with the license agreement in 2013. The company was built specifically around a discovery of a novel method of treating spinal muscular atrophy using gene therapy. AveXis was acquired by Novartis in 2018 for USD 8.7 billion.

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

<span class="mw-page-title-main">GenScript Biotech</span> Biotechnology group

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a New Jersey-based biotech company. It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. The company mainly provides life science research application instruments and services. It was listed on the Hong Kong Stock Exchange in 2015. The current rotating CEO of the firm is Shao Weihui, and its main subsidiaries include Legend Biotech, Probio Technology, and Bestzyme.

BeiGene, Ltd. is a China-based drug developer. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the multinational company headquartered in Cambridge, Massachusetts has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

References

  1. ↑ Phadnis, Aneesh (2017-09-05). "Indian-origin Vasant Narasimhan to head $48 billion pharma giant Novartis". Business Standard India. Retrieved 2018-08-15.
  2. ↑ Bisserbe, Noemie (2018-02-18). "Novartis CEO Steers Drug Maker Back to R&D". Wall Street Journal. ISSN   0099-9660 . Retrieved 2018-08-15.
  3. ↑ Phadnis, Aneesh (5 September 2017). "Indian-origin Vasant Narasimhan to head $48 billion pharma giant Novartis". Business Standard India. Retrieved 25 November 2019.
  4. ↑ Dandekar, Vikas; Sukumar, C. R. (21 August 2018). "There's an explosion of data & digital opportunities in Indian healthcare: Vasant Narasimhan, CEO, Novartis". The Economic Times. Retrieved 25 November 2019.
  5. 1 2 "Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor". Bloomberg.com. Bloomberg Technology. 4 September 2017. Retrieved 5 September 2017.
  6. 1 2 3 4 5 "Executive Profile – Vasant Narasimhan". Bloomberg. Retrieved 15 August 2018.
  7. ↑ Phadnis, Aneesh (September 4, 2017). "Indian-origin Vasant Narasimhan to head $48 billion pharma giant Novartis". Business Standard . Retrieved July 8, 2022. Narasimhan, 41, doctor from Harvard Medical School, is a second generation immigrant in the US. His parents moved there from Tamil Nadu in the 1970s.
  8. 1 2 "WEDDINGS/CELEBRATIONS; Srishti Gupta, Vasan Narasimhan". The New York Times . March 16, 2003. Retrieved July 8, 2022. His mother, Gira Narasimhan, a former nuclear engineer for Public Service Electric & Gas, is a lecturer in physics at Burlington County Community College in Pemberton, N.J. His father is the vice president for research and development at the Hoeganaes Corporation, a supplier and developer of industrial raw materials, in Cinnaminson, N.J.
  9. 1 2 3 LIVE: Vas Narasimhan (CEO of Novartis) & Dr. Srishti Gupta Narasimhan (Physician Leader in Health and Education) - South Asian Trailblazers , retrieved 2023-11-30
  10. ↑ "Vasant (Vas) Narasimhan" (PDF). Novartis. Archived from the original (PDF) on 5 September 2017. Retrieved 5 September 2017.
  11. ↑ Smale, Will (March 18, 2020). "'It was never my plan to be the boss of a huge company'". BBC . Retrieved July 8, 2022. There was also no let up in his summer holidays, as he was always volunteering overseas; helping to fight malaria in Gambia, tackling tuberculosis in Peru and child poverty in India.
  12. ↑ Gelles, David (August 1, 2019). "Vas Narasimhan of Novartis: 'We Are Not at All Prepared for a Pandemic'". The New York Times . Retrieved July 8, 2022. I went to the University of Chicago and did pre-med. Then for my junior year of college I went to Gambia where I worked with the Red Cross in malaria control. That was my first exposure to public health.
  13. ↑ Mlambo-Ngcuka, Phumzile (August 19, 2019). Redefining Leadership in the Age of the SDGs Accelerating and Scaling Up Delivery Through Innovation and Inclusion (PDF) (Report). Harvard Law School. p. 19. Retrieved July 8, 2022. Narasimhan knows this well. As age 20, Narasimhan took time off of college, to work with the Red Cross in Gambia.
  14. ↑ Narasimhan, Vasant; Brown, Hilary; Pablos-Mendez, Ariel; Adams, Orvill; Dussault, Gilles; Elzinga, Gijs; Nordstrom, Anders; Habte, Demissie; Jacobs, Marian; Solimano, Giorgio; Sewankambo, Nelson; Wibulpolprasert, Suwit; Evans, Timothy; Chen, Lincoln (2004-05-01). "Responding to the global human resources crisis". Lancet. 363 (9419): 1469–1472. doi:10.1016/S0140-6736(04)16108-4. ISSN   1474-547X. PMID   15121412. S2CID   34887437.
  15. ↑ Narasimhan, Vasant; Brown, Hilary; Pablos-Mendez, Ariel; Adams, Orvill; Dussault, Gilles; Elzinga, Gijs; Nordstrom, Anders; Habte, Demissie; Jacobs, Marian; Solimano, Giorgio; Sewankambo, Nelson; Wibulpolprasert, Suwit; Evans, Timothy; Chen, Lincoln (2004-05-01). "Responding to the global human resources crisis". The Lancet. 363 (9419): 1469–1472. doi:10.1016/S0140-6736(04)16108-4. ISSN   0140-6736. PMID   15121412. S2CID   34887437.
  16. 1 2 "Emerging Pharma Leaders: Vas Narasimhan". PharmExec. 3 October 2016. Retrieved 2023-04-24.
  17. 1 2 "Vasant Narasimhan". Novartis. Retrieved 2023-04-24.
  18. ↑ Times, Sarah Neville and Ralph Atkins, Financial (26 September 2017). "New Novartis chief eyes productivity revolution". SWI swissinfo.ch. Retrieved 2023-04-24.{{cite web}}: CS1 maint: multiple names: authors list (link)
  19. ↑ "Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018". Novartis. Retrieved 2023-04-24.
  20. 1 2 Mancini, Donato Paolo (2022-02-04). "Vas Narasimhan: the American trying to reshape Novartis". Financial Times. Retrieved 2023-06-27.
  21. ↑ Dunn, Andrew. "Novartis' CEO said gene therapy is a 'nuanced puzzle' everyone is trying to figure out, but he's still committed to the cutting-edge treatments". Business Insider. Retrieved 2023-06-27.
  22. ↑ "Novartis CEO eyeing RNA landscape for M&A to expand research 'gameboard'". www.spglobal.com. Retrieved 2023-06-27.
  23. ↑ Nathan-Kazis, Josh. "Novartis CEO to Wall Street: Don't Underplay What's Ahead for This Company". www.barrons.com. Retrieved 2023-06-27.
  24. ↑ Daniel, Ellen (2018-04-04). "GSK to buyout consumer healthcare business from Novartis for $13bn". Pharmaceutical Technology. Retrieved 2023-06-27.
  25. ↑ "Novartis to Spin Off Alcon as CEO Focuses on Finding Drugs". Bloomberg.com. 2018-06-29. Retrieved 2023-06-27.
  26. ↑ "Roche to repurchase equity stake held by Novartis". European Pharmaceutical Review. Retrieved 2023-06-27.
  27. ↑ "Novartis pushes deeper into nuclear medicine with $2.1 billion deal". Reuters. 2018-10-18. Retrieved 2023-06-27.
  28. ↑ Kuchler, Hannah (2021-07-21). "Novartis aims to beat rivals to novel $10bn cancer treatment market". Financial Times. Retrieved 2023-06-27.
  29. ↑ Tindera, Michela. "Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: 'It's A Challenge We Have To Solve'". Forbes. Retrieved 2023-06-27.
  30. ↑ Okun, Eli (2018-05-11). "Novartis CEO: 'We made a mistake' with Cohen payments". POLITICO. Retrieved 2023-06-27.
  31. ↑ "Novartis legal head resigns over Cohen payments". PMLive. 2018-05-16. Retrieved 2023-06-27.
  32. ↑ Thomas, Katie (2019-08-07). "Novartis C.E.O. Defends Company's Decision to Withhold False Data From the F.D.A." The New York Times. ISSN   0362-4331 . Retrieved 2023-06-27.
  33. ↑ Garde, Damian (August 7, 2019). "Novartis CEO in the hotseat after revelation that his company submitted falsified data to the FDA - The Boston Globe". BostonGlobe.com. Retrieved 2023-06-27.
  34. ↑ Tirrell, Meg (2019-08-14). "Novartis fires brother scientists alleged to be involved in data manipulation". CNBC. Retrieved 2023-06-27.
  35. ↑ Keystone-SDA/dos (2020-07-02). "Novartis pays big fine for bribing doctors in the US". SWI swissinfo.ch. Retrieved 2023-06-27.
  36. ↑ "Novartis CEO sets aside $700 million to settle doctor bribery lawsuit". Reuters. 2019-07-18. Retrieved 2023-06-27.
  37. ↑ "Novartis links bonuses to ethics in bid to rebuild reputation". Reuters. 2018-09-17. Retrieved 2023-06-27.
  38. ↑ "Board of Fellows". hms.harvard.edu. Retrieved 2023-04-24.
  39. ↑ "Authors". World Economic Forum. Retrieved 2018-08-15.
  40. ↑ "Vas Narasimhan of Novartis Becomes Chair of PhRMA Board". phrma.org. Retrieved 2023-04-24.
  41. ↑ "Novartis CEO, as incoming PhRMA chair, outlines 3 priorities for pharma after IRA setback". Fiercepharma.
  42. ↑ "Vasant (Vas) Narasimhan". www.africanparks.org. Retrieved 2023-04-24.
  43. ↑ "African Parks appoints new Chairperson of the Board". www.africanparks.org. Retrieved 2023-04-24.
  44. ↑ "Vas Narasimhan". Fortune. 2015-09-24. Archived from the original on 2018-08-16. Retrieved 2018-08-15.
  45. ↑ "WEDDINGS/CELEBRATIONS; Srishti Gupta, Vasant Narasimhan". The New York Times. 2003-03-16. ISSN   0362-4331 . Retrieved 2020-09-24.
  46. ↑ "Vas Narasimhan knew what to expect as Novartis CEO—or so he thought: NYT".
  47. ↑ "Vas Narasimhan - Agenda Contributor". World Economic Forum. Retrieved 2023-04-24.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.